HKG:2566

2 stories mentioning HKG:2566Updated 38d ago

Every FINWIRES story that references HKG:2566, newest first.

Hangzhou Jiuyuan Genetic Completes Hong Kong-Listed Share Full Circulation

Hangzhou Jiuyuan Genetic Biopharmaceutical (HKG:2566) completed the conversion of all its 136.3 million unlisted shares into Hong Kong-listed shares on Thursday, according to a same-day bourse filing.Shares of the firm were down over 1% in late morning trade on Friday.The listing of and dealing in converted shares on the Hong Kong Stock Exchange began at 9:00 am on Friday.

HKG:2566

Asia55d ago

Jiuyuan Genetic Biopharmaceutical Gets China Nod for Weight Management Drug Trial

Hangzhou Jiuyuan Genetic Biopharmaceutical (HKG:2566) obtained clinical trial approval for the JY54 Injection from China's National Medical Products Administration, according to a Tuesday Hong Kong bourse filing.The product is intended to contribute to glycemic control and weight management.

HKG:2566

Track with the FINWIRES app suite

FolioX

Track HKG:2566 in your portfolio

WheelAI

Analyze HKG:2566 options with the wheel strategy

StockInsider

See market sentiment on HKG:2566